14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GRAL vs CRL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Charles River Laboratories International, Inc. (CRL) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas CRL carries 48.0/100 (HOLD) at $335.52 (25.9x Forward P/E, 14.3% operating margin).
Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. CRL 48.0/100 HOLD), CRL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.3% vs. -332.0% operating margin) and revenue trajectory (-2.2% vs. +3.7% YoY).
Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile CRL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRAL vs CRL. Trailing 12-month operating profitability (GRAL -332.0% vs CRL 14.3%) and valuation multiples (GRAL 1.1x vs CRL 25.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Diagnostics & Research value chain with $16.2B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment20.8% of Rev ($827M)
90D Engineering Disclosures0 Published
Investor FAQ GRAL vs CRL Key Questions & Quantitative Answers
As of Nov 16, 2026, Charles River Laboratories International, Inc. (CRL) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas CRL carries 48.0/100 (HOLD) at $335.52 (25.9x Forward P/E, 14.3% operating margin). Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. CRL 48.0/100 HOLD), CRL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.3% vs. -332.0% operating margin) and revenue trajectory (-2.2% vs. +3.7% YoY). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile CRL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRL leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with CRL at -2.2% YoY revenue growth and +523.6% YoY earnings growth on $3.98B TTM revenue (35.1% gross margin, 14.3% operating margin). On trailing 12-month operating scale, GRAL generates $167M in USD-normalized revenue versus $3.98B for CRL. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus 20.8% of Rev ($827M) (0 disclosures) for CRL.
GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas CRL trades at 25.9x Forward P/E, N/M Trailing P/E, 0.13x PEG, and 4.1x EV/Revenue (22.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus CRL (1.3% ROE) capital efficiency.
In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, CRL carries 38.8% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 68% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.